Department of Pharmaceutical Chemistry, Noida Institute of Engineering and Technology (Pharmacy Institute), Plot No. 19, Knowledge Park-II, Greater Noida, Uttar Pradesh, 201306, India.
Department of Pharmaceutical Chemistry, Maharishi Arvind College of Pharmacy, Ambabari Circle, Jaipur, Rajasthan, 302039, India.
Curr Org Synth. 2024;21(8):976-1013. doi: 10.2174/0115701794260740231010111408.
Two significant families of compounds i.e. 1,3,4-oxadiazole and benzimidazole, have undergone extensive investigation into their pharmacological characteristics and possible therapeutic applications. Both classes have shown their potential in a variety of applications, and because of their synergistic interactions, they may have an even better therapeutic impact when combined.
To produce a specific molecule with potent therapeutic properties, it is now common methods to combine at least two pharmacophores. This facilitates interaction with several targets, enhances biological functions, or eliminates adverse effects associated with them.
The synthesis of benzimidazole-1,3,4-oxadiazole hybrid compounds has recently involved the use of several synthetic techniques, all of which are detailed in the literature along with the advantages and disadvantages. It has been noted that the structure-activity relationship relates their pharmacological actions to their molecular structure. In order to set the stage for future research, the study aims to provide researchers with an effective toolbox and an understanding of benzimidazole and 1,3,4-oxadiazole hybrid compounds.
1,3,4-恶二唑和苯并咪唑这两类化合物在药理学特性及其潜在治疗应用方面已经进行了广泛的研究。这两类化合物都在各种应用中显示出了潜力，并且由于它们的协同作用，当它们结合使用时可能会产生更好的治疗效果。
为了产生具有强大治疗特性的特定分子，现在通常的方法是将至少两个药效团结合起来。这有助于与多个靶点相互作用，增强生物功能，或消除与之相关的不良反应。
苯并咪唑-1,3,4-恶二唑杂环化合物的合成最近已经涉及到几种合成技术的使用，所有这些技术都在文献中详细介绍，同时还介绍了它们的优缺点。已经注意到，结构-活性关系将它们的药理作用与其分子结构联系起来。为了为未来的研究奠定基础，本研究旨在为研究人员提供一个有效的工具包，并了解苯并咪唑和 1,3,4-恶二唑杂环化合物。
